|Table of Contents|

Investigation of expression profiles of tumour microenvironment cells and the correlation with clinical survival probability in non-small cell lung cancer

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2021 05
Page:
777-781
Research Field:
Publishing date:

Info

Title:
Investigation of expression profiles of tumour microenvironment cells and the correlation with clinical survival probability in non-small cell lung cancer
Author(s):
QIAO Tianyun; XIONG Yanlu; FENG Yangbo; ZHOU Yongsheng; XIN Shaowei; ZHAO Jinbo; HAN Yong
Department of Thoracic Surgery,Tangdu Hospital,Air Force Medical University,Shaanxi Xi'an 710038,China.
Keywords:
tumor microenvironment; immune cells; non-small cell lung cancer; immunotherapy; survival probability
PACS:
R734.2
DOI:
10.3969/j.issn.1672-4992.2021.05.013
Abstract:
Objective:To explore the expression profiles of tumor microenvironment cells in non-small cell lung cancer and the correlation with clinical survival probability.Methods:Firstly,we obtained gene expression data and relevant clinical information of lung adenocarcinoma and lung squamous cell carcinoma from the TCGA database.Then,the expression differences of several common tumor microenvironment cells between cancer tissues and adjacent lung cancer tissues were analyzed by non-parametric test,as well as the relationship between the degree of cell invasion and the survival probability of non-small cell lung cancer,and the multi-factor survival analysis was carried out.Results:In lung adenocarcinoma,the expressions of CD4+,CD8+T cells,endothelial cells and macrophages were low,while those of B cells and CAFs cells were high.The survival probability was positively correlated with CD4+T cells.In lung squamous cell carcinoma,the expression of endothelial cells and macrophages was low,and the expression of CAFs was high.The survival probability was positively correlated with CD8+T cells.Conclusion:The expression of infiltrating cells is different in the tumor microenvironment of lung adenocarcinoma and lung squamous cell carcinoma,and it is related to the clinical survival probability.

References:

[1]BRAY F,FERLAY J,SOERJOMATARAM I,et al.Global cancer statistics 2018:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries［J］.CA Cancer J Clin,2018,68:394-424.
[2]MILLER KD,NOGUEIRA L,MARIOTTO AB,et al.Cancer treatment and survivorship statistics,2019［J］.CA Cancer J Clin,2019,69:363-385.
[3] KILLOCK D.Sequencing cells of the immune TME［J］.Nat Rev Clin Oncol,2018,15:531.
[4]GAO S,YANG DJ,FANG Y,et al.Engineering nanoparticles for targeted remodeling of the tumor microenvironment to improve cancer immunotherapy［J］.Theranostics,2019,9:126-151.
[5]GIRALDO NICO A,SANCHEZ-SALAS R,PESKE JD,et al.The clinical role of the TME in solid cancer［J］.Br J Cancer,2019,120:45-53.
[6]MIYAI Y,ESAKI N,TAKAHASHI M,et al.Cancer-associated fibroblasts that restrain cancer progression:Hypotheses and perspectives［J］.Cancer Sci,2020,111:1047-1057.
[7]REYMOND N,DAGUA BB,RIDELY AJ,et al.Crossing the endothelial barrier during metastasis［J］.Nat Rev Cancer,2013,13:858-870.
[8]PAAUWE M,SCHOONDERWOERD MJA,HELDERMAN RFCP,et al.Endoglin expression on cancer-associated fibroblasts regulates invasion and stimulates colorectal cancer metastasis［J］.Clin Cancer Res,2018,24:6331-6344.
[9]CIMA I,KONG SL,SENGUPTA D,et al.Tumor-derived circulating endothelial cell clusters in colorectal cancer［J］.Sci Transl Med,2016,8:345ra89.
[10]CAVACO A,REZAEI M,NILAND S,et al.Collateral damage intended-cancer-associated fibroblasts and vasculature are potential targets in cancer therapy［J］.Int J Mol Sci,2017,18:2355.
[11]HUANG D,LI TT,WANG L,et al.Hepatocellular carcinoma redirects to ketolysis for progression under nutrition deprivation stress［J］.Cell Res,2016,26:1112-1130.
[12]JING XM,YANG FM,SHAO CC,et al.Role of hypoxia in cancer therapy by regulating the tumor microenvironment［J］.Mol Cancer,2019,18:157.
[13] WHITE KA,KISOR K,BARBER DL.Intracellular pH dynamics and charge-changing somatic mutations in cancer［J］.Cancer Metastasis Rev,2019,38:17-24.
[14]ROMA-RODRIGUES C,MENDES R,BAPTISTA PV,et al.Targeting tumor microenvironment for cancer therapy［J］.Int J Mol Sci,2019,20(4):840.
[15]ANDERSEN MH.The targeting of immunosuppressive mechanisms in hematological malignancies［J］.Leukemia,2014,28:1784-92.
[16]YU LB,LIU QY,HUO J,et al.Cancer-associated fibroblasts induce immunotherapy resistance in hepatocellular carcinoma animal model［J］.Cell Mol Biol（Noisy-le-grand),2020,66:36-40.
[17]HAUGE A,ROFSTAD EK.Antifibrotic therapy to normalize the tumor microenvironment［J］.J Transl Med,2020,18:207.
[18]FU CL,TYAGI R,CHIN AC,et al.Inositol polyphosphate multikinase inhibits angiogenesis via inositol pentakisphosphate-induced HIF-1α degradation［J］.Circ Res,2018,122:457-472.
[19]CAO YH.VEGF-targeted cancer therapeutics-paradoxical effects in endocrine organs［J］.Nat Rev Endocrinol,2014,10:530-539.
[20]FARHOOD B,NAJAFI M,MORTEZAEE K.CD8 cytotoxic T lymphocytes in cancer immunotherapy:A review［J］.J Cell Physiol,2019,234:8509-8521.
[21]BAUMANN T,DUNKEL A,SCHMID C,et al.Regulatory myeloid cells paralyze T cells through cell-cell transfer of the metabolite methylglyoxal［J］.Nat Immunol,2020,21:555-566.
[22]AGUDELO GPA,BERGER SL.Genetics meets epigenetics in Treg cells and autoimmunity［J］.Immunity,2020,52:897-899.
[23]CAMIDGE DR,DOEBELE RC,KERR KM.Comparing and contrasting predictive biomarkers for immunotherapy and targeted therapy of NSCLC［J］.Nat Rev Clin Oncol,2019,16:341-355.
[24]RODALLEC A,SICARD G,FANCIULLINO R,et al.Turning cold tumors into hot tumors:harnessing the potential of tumor immunity using nanoparticles［J］.Expert Opin Drug Metab Toxicol,2018,14:1139-1147.

Memo

Memo:
National Natural Science Foundation of China(No.81772462）；国家自然科学基金面上项目(编号：81772462)
Last Update: 2021-01-29